
    
      This is a prospective, multicenter, longitudinal, single-cohort, observational study in
      participants with MDD who have responded to, and are continuing to respond to and receive, an
      oral antidepressant treatment regimen. The study will consist of 2 parts: a screening phase
      of up to 2 weeks, and an observational phase of variable duration.
    
  